Camargo

MAY 10, 2021

Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. Triple-negative breast cancer. First-line bladder cancer. First-line bladder cancer. Third-line stomach cancer. 7 Yes, 2 No.

Development 185

Development Clinical Trials Clinical Trials Trials 185

pharmaphorum

SEPTEMBER 28, 2021

Merck & Co’s FDA approval for Keytruda in advanced liver cancer looks secure, after an Asian clinical trial found that the cancer immunotherapy improved survival in these patients. That data is now in, and it’s good news, according to Merck, which will now be able to apply for a full FDA approval.

FDA Approval 52

FDA Approval Trials Clinical Trials Clinical Trials 52

BioTech 365

JANUARY 18, 2022

DGAP-News: ABIVAX / Key word(s): Study results/Conference 19.01.2022 / 08:00 The issuer is solely responsible for the content of this announcement. Abivax’s phase 1/2 clinical study results of ABX196 in liver cancer to be presented on Jan. 21, at ASCO … Continue reading →

40

40

BioTech 365

NOVEMBER 30, 2021

DGAP-News: ABIVAX / Key word(s): Study results 30.11.2021 / 18:00 The issuer is solely responsible for the content of this announcement. Abivax’s phase 1/2 clinical study results of ABX196 in liver cancer show good tolerability and promising signals of clinical … Continue reading →

40

40

BioTech 365

APRIL 22, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: XYZeq: A better map of cell diversity.Not all cancer cells within a tumor are created equal; nor do all immune cells (or all liver or brain cells) … Continue reading →

Research 40

Research 40

BioTech 365

APRIL 5, 2021

DGAP-News: Epigenomics AG / Key word(s): Study results/Study 06.04.2021 / 07:59 The issuer is solely responsible for the content of this announcement. Study reported in BMC Gastroenterology demonstrates significantly better performance characteristics of Epigenomics’ liver cancer panel compared to the … Continue reading →

40

40

BioTech 365

MARCH 5, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Study: Combined liver-cytokine humanization rescues circulating red blood cells for testing drugs.In

Drugs 40

Drugs Research 40

World of DTC Marketing

JUNE 5, 2021

Obesity and Cancer. Being overweight or having obesity are linked with a higher risk of getting 13 types of cancer. These cancers make up 40% of all cancers diagnosed in the United States each year. Being overweight and having obesity are linked with a higher risk of getting 13 kinds of cancer. Gallbladder.

Medicine 193

Medicine Gene Genetics Research 193

Pharmaceutical Technology

SEPTEMBER 23, 2022

The recent FDA approval of Fennec Pharmaceuticals’ drug PEDMARK (sodium thiosulfate injection) marks a significant advance for cancer treatment-associated hearing loss therapies, amidst a bid to improve quality of life for cancer patients. The current standard of care for many cancers is cisplatin chemotherapy or platinum therapy.

Drugs 130

Drugs FDA Approval Clinical Trials Clinical Trials 130

World of DTC Marketing

MAY 16, 2022

Mounjaro, Lilly’s new diabetes drug, is sure to be in high demand initially after launch, but patients should be aware of its side effects. According to Lilly side, the effects include “Mounjaro may cause tumors in the thyroid, including thyroid cancer and Inflammation of the pancreas (pancreatitis).”

Drugs 218

Drugs Pharma Companies Clinical Trials Clinical Trials 218

pharmaphorum

FEBRUARY 22, 2021

AstraZeneca has suffered a setback after it voluntarily withdrew its cancer immunotherapy Imfinzi (durvalumab) in a bladder cancer indication in the US. It’s news that will likely hand market share to Roche and Pfizer/Merck KGaA, whose respective immunotherapies Tecentriq and Bavencio have bladder cancer indications.

Trials 52

Trials Sales Marketing Drugs 52

Drug Discovery World

OCTOBER 21, 2022

News round-up for 17-21 October by DDW Digital Content Editor Diana Spencer . Amid continued concern about antibiotic resistance, the headline news this week was the discovery of a new antibiotic that could be effective against some of the most treatment-resistant pathogens. . New antibiotic could kill resistant pathogens .

Drugs 52

Drugs Allergies Clinical Trials Clinical Trials 52

pharmaphorum

APRIL 27, 2021

Dosing can start once again in uniQure’s phase 3 trial of its haemophilia B gene therapy, after the FDA concluded that a case of liver cancer seen in the study was unlikely to be caused by the treatment. . The post FDA lifts hold on uniQure gene therapy after cancer case review appeared first on.

Gene Therapy 52

Gene Therapy Gene Genome Genomics 52

The Pharma Data

DECEMBER 21, 2020

FDA Approves First Oral Hormone Therapy for Advanced Prostate Cancer. 21, 2020 — Orgovyx (relugolix) is now approved to treat advanced prostate cancer and is the first oral hormone therapy approved for this indication, the U.S. More News Resources. Professional. MONDAY, Dec. Food and Drug Administration announced Friday.

Hormones 52

Hormones FDA Approval Trials Drugs 52

Drug Discovery World

NOVEMBER 24, 2023

AstraZeneca has announced that the National Institute for Health and Care Excellence (NICE) has recommended Imfinzi (durvalumab) in combination with gemcitabine and cisplatin (chemotherapy) for NHS use in England and Wales for the first-line treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer (BTC).

HR 52

HR Licensing Licensing Trials 52

Drug Discovery World

NOVEMBER 1, 2023

Many drug discovery companies took the opportunity to share their latest cancer research findings. Amivantamab, Janssen Data from the Phase III MARIPOSA study showed amivantamab plus lazertinib improved PFS by 30% compared to osimertinib in patients with first-line advanced EGFR-mutated non-small cell lung cancer (NSCLC).

Clinical Trials 59

Clinical Trials Clinical Trials Trials HR 59

Delveinsight

SEPTEMBER 9, 2021

A collaboration valued more than USD 3 billion, Genentech, a member of the Roche Group, declared it will collaborate with Adaptimmune for developing and commercializing allogeneic T-cell therapies to treat multiple cancer indications. A portion of the new funding will also be utilized to improve the Breath Biopsy platform.

FDA Approval 73

FDA Approval Development Research Production 73

pharmaphorum

FEBRUARY 22, 2021

Bluebird Bio’s decision to hit pause on the launch of Zynteglo for beta thalassaemia after two cases of cancer were seen in a clinical trial could see fears over the safety of viral vectors used to deliver gene therapies resurface. . million in Europe.

Gene Therapy 52

Gene Therapy Gene Gene Sequencing Gene Expression 52

Pharmaceutical Technology

JULY 22, 2022

The World Health Organization (WHO) further stated that at least 18 of the children underwent liver transplants, and one had died. Helen Branswell, an infectious diseases and health reporter at the news website Stat News, shared an article on a monkeypox case being reported in the US, amid rising cases in Spain, Portugal, and Europe.

Vaccination 130

Vaccination Vaccine Life Science Immune Response 130

XTalks

JANUARY 28, 2022

Up to 50 percent of patients will develop metastatic disease, mainly spreading to the liver, making treatment difficult and limited. Related: Cancer Blood Test Developed by University of Oxford Researchers Can Detect Metastasis. Uveal melanoma is a rare and aggressive type of melanoma of the eye.

FDA Approval 98

FDA Approval Development Licensing Licensing 98

Delveinsight

DECEMBER 22, 2020

Servier Acquires Agios’ Cancer Portfolio in a USD 2 Billion Deal. After the news broke, shares of Agios soared in premarket trading. The post Agios’ cancer pipeline auction; uniQure’s gene therapy on hold; Ultragenyx, Mereo Deal; aTyr Pharma Trial appeared first on DelveInsight Business Research.

Gene Therapy 52

Gene Therapy Gene Trials Clinical Trials 52

The Pharma Data

NOVEMBER 9, 2020

The results were presented at The Society for the Immunotherapy of Cancer 35 th Anniversary Annual Meeting. Addressing Unmet Needs in Cancer Immunotherapy. Taken together, these barriers present a significant unmet need to improve the efficacy ICIs and expand their potentially curative benefits to more patients with advanced cancers.

Immune Response 40

Immune Response Containment Trials Clinical Trials 40

The Pharma Data

OCTOBER 20, 2020

8 months in similar patients with metastatic breast cancer in the third line setting without BriaCell’s treatment; Additional overall survival data will be presented at the 2020 San Antonio Breast Cancer Symposium®, December 9 – 11. Breast Cancer Res Treat. Overall Survival of 13. BERKELEY, Calif.

Containment 52

Containment Research Regulation Manufacturing 52

The Pharma Data

OCTOBER 19, 2020

Two presentations will be delivered by Nanobiotix and two will be delivered by the University of Texas MD Anderson Cancer Center. 11 from 12:15 pm – 12:25 pm EST. In the United States, the Company has started the regulatory process to commence a phase III clinical trial in locally advanced head and neck cancers.

Containment 52

Containment Clinical Trials Clinical Trials Immune Response 52

The Pharma Data

SEPTEMBER 16, 2020

New and updated data from across our broad cancer portfolio including phase III results in breast, lung and prostate cancers. New integrated analyses from our tumour agnostic Rozlytrek ® (entrectinib) clinical development programme.

HR 52

HR Medicine Hormones Trials 52

Pharma Times

APRIL 9, 2024

Hepatocellular carcinoma is one of the leading causes of cancer-related deaths worldwide

Vaccination 125

Vaccination Vaccine Research 125

The Pharma Data

JULY 21, 2021

. “This Breakthrough Therapy Designation underscores the need for more treatment options for these patients and the utility of venetoclax to potentially treat different forms of blood cancer.” In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis.

Medicine 52

Medicine Vaccination Vaccine Clinical Trials 52

The Pharma Data

MAY 14, 2021

Product Name: Fatty Liver Case Study cb | Blue Heron Health News. Click here to get Fatty Liver Case Study cb | Blue Heron Health News at discounted price while it’s still available… All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors.

Doctors 52

Doctors Doctor Production Medicine 52

The Pharma Data

OCTOBER 29, 2020

Today’s news builds upon this progress and provides hope to people living with alopecia areata.” Periodic skin examination is recommended for patients who are at increased risk for skin cancer. Liver Enzyme Elevations – Olumiant treatment was associated with increased incidence of liver enzyme elevation compared to placebo.

Dermatology 52

Dermatology Development Medicine Clinical Trials 52

The Pharma Data

MAY 4, 2021

Consider the risks and benefits of Olumiant prior to initiating therapy in patients with a known malignancy other than a successfully treated non-melanoma skin cancer (NMSC) or when considering continuing Olumiant in patients who develop a malignancy. To learn more about Lilly , please visit us at www.lilly.com and www.lilly.com/news.

Licensing 40

Licensing Licensing FDA Approval Development 40

The Pharma Data

JANUARY 10, 2021

The new year began with a fairly low level of clinical trial news. Harpoon Therapeutics dosed the first patient with HPN328 in its Phase I/II trial of small cell lung cancer (SCLC) and other tumors associated with DLL3 expression. Here’s a look. COVID-19-Related. Cerecor announced results from its exploratory Phase II U.S.

Gene Therapy 52

Gene Therapy Trials Gene Clinical Trials 52

pharmaphorum

AUGUST 4, 2022

Two phase 3 trials of Merck & Co’s Keytruda in metastatic castration-resistant prostate cancer (CRPC) and advanced liver cancer have ended in failure, proving once again that cancer immunotherapy studies can be a hit-and-miss affair. Lenvima combination.

Trials 91

Trials Hormones Drugs Clinical Development 91

The Pharma Data

JUNE 30, 2021

This is promising news for the IBD community.” 1-6 No new safety risks were identified. 1-6 No new safety risks were identified. Lymphoma and other cancers, including skin cancers, can happen in people taking RINVOQ. 1 The exposure-adjusted event rates of adverse events per 100 patient years were 16.0

Medicine 52

Medicine Bacteria Vaccination Vaccine 52

pharmaphorum

JUNE 1, 2022

The new Imaging Lab business will deploy AI, data mining, and radiomics technologies to medical imaging data generated in cancer trials, said Median. specificity in detecting cancer in lung nodules from a cohort of 1,760 patients. specificity in detecting cancer in lung nodules from a cohort of 1,760 patients.

Trials 80

Trials Clinical Trials Clinical Trials FDA Approval 80

pharmaphorum

NOVEMBER 10, 2022

Those adult patients who have had sorafenib as a treatment for HCC, a type of primary liver cancer – and who exhibit Child Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 – are now NICE recommended to be treated with cabozantinib. months with cabozantinib and 8.0

Medicine 52

Medicine Trials 52

Drug Discovery World

MAY 18, 2023

Scientists in Japan have used a novel technique to identify a protein complex degraded by autophagy that has a possible role in liver cancer. The post Study identifies protein complex with possible role in liver cancer appeared first on Drug Discovery World (DDW).

Protein 52

Protein Scientist Medicine Regulation 52

Drug Discovery World

APRIL 16, 2023

The mainstays of curative therapies for early-stage HCC include surgical resection and thermal ablation, a treatment that destroys the cancer cells with heat or cold. The post Results revealed for ‘practice-changing’ combination liver cancer therapy appeared first on Drug Discovery World (DDW).

Trials 52

Trials Clinical Trials Clinical Trials Drugs 52